Shattuck Labs, Inc.

Clinical trials sponsored by Shattuck Labs, Inc., explained in plain language.

Shattuck Labs, Inc. STTK NASDAQ

A clinical-stage biotech developing immunotherapies for cancer.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Not yet recruiting 1 Not yet finished but already full! 1 Completed 1 Terminated 1

New drug SL-325 tested in healthy volunteers for safety

Knowledge-focused Ongoing

This early-stage study is testing a new drug, SL-325, in 72 healthy volunteers to see if it is safe and how the body processes it. Participants receive either the drug or a placebo, and researchers monitor for side effects. This study does not aim to treat any disease but to gath…

Phase 1 • Sponsor: Shattuck Labs, Inc. • Aim: Knowledge-focused

Last updated Jun 27, 2026 12:26 UTC

Shattuck Labs, Inc.

New drug SL-325 tested in healthy volunteers for safety